Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

5-Azacitidine in Patients with IDH1/2-mutant Recurrent Glioma.

Federici L, Capelle L, Annereau M, Bielle F, Willekens C, Dehais C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Idbaih A, Lemare F, de Botton S, Sanson M, Touat M.

Neuro Oncol. 2020 Mar 26. pii: noaa074. doi: 10.1093/neuonc/noaa074. [Epub ahead of print] No abstract available.

PMID:
32215616
2.

Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations.

Boisseau W, Euskirchen P, Mokhtari K, Dehais C, Touat M, Hoang-Xuan K, Sanson M, Capelle L, Nouet A, Karachi C, Bielle F, Guégan J, Marie Y, Martin-Duverneuil N, Taillandier L, Rousseau A, Delattre JY, Idbaih A.

Oncologist. 2019 Dec;24(12):1584-1592. doi: 10.1634/theoncologist.2019-0223. Epub 2019 Jul 25.

3.

PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited.

Knauss S, Preusse C, Allenbach Y, Leonard-Louis S, Touat M, Fischer N, Radbruch H, Mothes R, Matyash V, Böhmerle W, Endres M, Goebel HH, Benveniste O, Stenzel W.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 10;6(3):e558. doi: 10.1212/NXI.0000000000000558. eCollection 2019 May.

4.

Hospitalisations with infections related to antimicrobial-resistant bacteria from the French nationwide hospital discharge database, 2016.

Opatowski M, Tuppin P, Cosker K, Touat M, De Lagasnerie G, Guillemot D, Salomon J, Brun-Buisson C, Watier L.

Epidemiol Infect. 2019 Jan;147:e144. doi: 10.1017/S0950268819000402.

5.

Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade.

Dunn IF, Du Z, Touat M, Sisti MB, Wen PY, Umeton R, Dubuc AM, Ducar M, Canoll PD, Severson E, Elvin JA, Ramkissoon SH, Lin JR, Cabrera L, Acevedo B, Sorger PK, Ligon KL, Santagata S, Reardon DA.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00190. Epub 2018 Nov 27. No abstract available.

6.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.

7.

A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case-Control Study.

Touat M, Opatowski M, Brun-Buisson C, Cosker K, Guillemot D, Salomon J, Tuppin P, de Lagasnerie G, Watier L.

Appl Health Econ Health Policy. 2019 Jun;17(3):381-389. doi: 10.1007/s40258-018-0451-1.

8.

Microfluidic active loading of single cells enables analysis of complex clinical specimens.

Calistri NL, Kimmerling RJ, Malinowski SW, Touat M, Stevens MM, Olcum S, Ligon KL, Manalis SR.

Nat Commun. 2018 Nov 14;9(1):4784. doi: 10.1038/s41467-018-07283-x.

9.

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.

Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM.

J Clin Oncol. 2018 Oct 23:JCO2018789990. doi: 10.1200/JCO.2018.78.9990. [Epub ahead of print]

10.

Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.

Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA network.

Acta Neuropathol Commun. 2018 Sep 7;6(1):89. doi: 10.1186/s40478-018-0594-1.

11.

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.

Touat M, Gratieux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, Perkins G, Blons H, Ligon KL, Idbaih A, Hollebecque A, Gimenez-Roqueplo AP, Laurent-Puig P, Sanson M, Villa C, Di Stefano AL.

Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17. No abstract available.

PMID:
30120137
12.

Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer.

Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K, Szwebel TA, Kramkimel N, Lethrosne C, Bruch JF, Laly P, Cadranel J, Weiss N, Béhin A, Allenbach Y, Benveniste O, Lenglet T, Psimaras D, Stenzel W, Léonard-Louis S.

Neurology. 2018 Sep 4;91(10):e985-e994. doi: 10.1212/WNL.0000000000006124. Epub 2018 Aug 8. Erratum in: Neurology. 2019 Aug 6;93(6):280.

PMID:
30089619
13.

Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.

Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, Fassò M, Osborne S, Molinero L, O'Hear C, Grossman W, Baehring J.

J Neurooncol. 2018 Nov;140(2):317-328. doi: 10.1007/s11060-018-2955-9. Epub 2018 Aug 2.

PMID:
30073642
14.

Encephalopathy associated with a reversible splenial lesion in riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.

Touat M, Michaud M, Alamowitch S, Maisonobe T, Acquaviva-Bourdain C, Laforêt P.

Rev Neurol (Paris). 2018 Dec;174(10):747-750. doi: 10.1016/j.neurol.2017.12.004. Epub 2018 Jul 30. No abstract available.

PMID:
30072122
15.

FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas.

Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M, Trisolini E, Meunier S, Schmitt Y, Idbaih A, Hoang-Xuan K, Delattre JY, Mokhtari K, Di Stefano AL, Sanson M.

Neurology. 2018 Jun 5;90(23):e2086-e2094. doi: 10.1212/WNL.0000000000005658. Epub 2018 May 4.

PMID:
29728520
16.

IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.

Appay R, Tabouret E, Macagno N, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA Network.

Neuro Oncol. 2018 Apr 9;20(5):716-718. doi: 10.1093/neuonc/noy014. No abstract available.

17.

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.

Touat M, Sourisseau T, Dorvault N, Chabanon RM, Garrido M, Morel D, Krastev DB, Bigot L, Adam J, Frankum JR, Durand S, Pontoizeau C, Souquère S, Kuo MS, Sauvaigo S, Mardakheh F, Sarasin A, Olaussen KA, Friboulet L, Bouillaud F, Pierron G, Ashworth A, Lombès A, Lord CJ, Soria JC, Postel-Vinay S.

J Clin Invest. 2018 Apr 2;128(4):1671-1687. doi: 10.1172/JCI90277. Epub 2018 Mar 19.

18.

Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.

Delahousse J, Verlingue L, Broutin S, Legoupil C, Touat M, Doucet L, Ammari S, Lacroix L, Ducreux M, Scoazec JY, Malka D, Paci A, Hollebecque A.

Eur J Cancer. 2018 Feb;90:83-91. doi: 10.1016/j.ejca.2017.11.024. Epub 2018 Jan 4.

PMID:
29274619
19.

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Bahleda R, Le Deley MC, Bernard A, Chaturvedi S, Hanley M, Poterie A, Gazzah A, Varga A, Touat M, Deutsch E, Massard C, Van De Velde H, Hollebecque A, Sallansonnet-Froment M, Ricard D, Taillia H, Angevin E, Ribrag V, Soria JC.

Invest New Drugs. 2018 Aug;36(4):619-628. doi: 10.1007/s10637-017-0531-3. Epub 2017 Nov 2.

PMID:
29094232
20.

Neurological toxicities associated with immune-checkpoint inhibitors.

Touat M, Talmasov D, Ricard D, Psimaras D.

Curr Opin Neurol. 2017 Dec;30(6):659-668. doi: 10.1097/WCO.0000000000000503. Review.

PMID:
28938341
21.

Glioblastoma targeted therapy: updated approaches from recent biological insights.

Touat M, Idbaih A, Sanson M, Ligon KL.

Ann Oncol. 2017 Jul 1;28(7):1457-1472. doi: 10.1093/annonc/mdx106. Review.

22.

Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy.

Boisseau W, Touat M, Berzero G, Savatovsky J, Marabelle A, Touitou V, Ricard D, Malouf G, Psimaras D.

Eur J Cancer. 2017 Sep;83:28-31. doi: 10.1016/j.ejca.2017.05.036. Epub 2017 Jul 12. No abstract available.

PMID:
28710954
23.

Acute Frontal Lobe Dysfunction Following Prefrontal Low-Frequency Repetitive Transcranial Magnetic Stimulation in a Patient with Treatment-Resistant Depression.

Carle G, Touat M, Bruno N, Galanaud D, Peretti CS, Valero-Cabré A, Levy R, Azuar C.

Front Psychiatry. 2017 May 30;8:96. doi: 10.3389/fpsyt.2017.00096. eCollection 2017.

24.

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.

Mondesir J, Willekens C, Touat M, de Botton S.

J Blood Med. 2016 Sep 2;7:171-80. doi: 10.2147/JBM.S70716. eCollection 2016. Review.

25.

Radiation plus Chemotherapy in Low-Grade Glioma.

Touat M, Idbaih A, Sanson M.

N Engl J Med. 2016 Aug 4;375(5):489-90. doi: 10.1056/NEJMc1605897. No abstract available.

PMID:
27518678
26.

Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma.

Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, Touitou V, Franck N, Kramkimel N, Borden A, Touat M, Ricard D, Verny M, Maisonobe T, Psimaras D.

Ann Oncol. 2016 Jul;27(7):1352-3. doi: 10.1093/annonc/mdw126. Epub 2016 Mar 2. No abstract available.

27.

Recurrence of Cerebral Amyloid Angiopathy-Related Inflammation: A Report of Two Cases from the iCAβ International Network.

DiFrancesco JC, Touat M, Caulo M, Gallucci M, Garcin B, Levy R, Uncini A, Piazza F.

J Alzheimers Dis. 2015;46(4):1071-7. doi: 10.3233/JAD-150070.

PMID:
26402633
28.

Emerging circulating biomarkers in glioblastoma: promises and challenges.

Touat M, Duran-Peña A, Alentorn A, Lacroix L, Massard C, Idbaih A.

Expert Rev Mol Diagn. 2015;15(10):1311-23. doi: 10.1586/14737159.2015.1087315. Review.

29.

Targeting FGFR Signaling in Cancer.

Touat M, Ileana E, Postel-Vinay S, André F, Soria JC.

Clin Cancer Res. 2015 Jun 15;21(12):2684-94. doi: 10.1158/1078-0432.CCR-14-2329. Review.

30.

Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival.

dos Santos MA, Pignon JP, Blanchard P, Lefeuvre D, Levy A, Touat M, Louvel G, Dhermain F, Soria JC, Deutsch E, Le Teuff G.

J Neurooncol. 2015 Jun;123(2):307-14. doi: 10.1007/s11060-015-1802-5. Epub 2015 May 15. Review.

PMID:
25975195
31.

Adapting the drivers to the road: a new strategy for cancer evolution?

Touat M, Dhermain F, André F, Sanson M.

Ann Oncol. 2015 May;26(5):827-9. doi: 10.1093/annonc/mdv137. Epub 2015 Mar 6. No abstract available.

32.

Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.

Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, Savatovsky J, Touat M, Belaid H, Kamoun A, Idbaih A, Houillier C, Luo FR, Soria JC, Tabernero J, Eoli M, Paterra R, Yip S, Petrecca K, Chan JA, Finocchiaro G, Lasorella A, Sanson M, Iavarone A.

Clin Cancer Res. 2015 Jul 15;21(14):3307-17. doi: 10.1158/1078-0432.CCR-14-2199. Epub 2015 Jan 21.

33.

Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486).

Touat M, Lombardi G, Farina P, Kalamarides M, Sanson M.

Acta Neurochir (Wien). 2014 Oct;156(10):1831-5. doi: 10.1007/s00701-014-2188-4. Epub 2014 Jul 31.

PMID:
25078073

Supplemental Content

Support Center